SCM
SLNO

Soleus Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Soleus Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$838K – 105
2025
Q2 		$838K Sell
10,000
-140,000
-93% -$10.5M 0.06% 87
2025
Q1 		$10.7M Buy
+150,000
New +$7.3M 0.77% 34
2023
Q4 		– Sell
-325,000
Closed -$9.59M – 99
2023
Q3 		$9.59M Buy
+325,000
New +$1.97M 0.88% 37

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Soleus Capital Management's SLNO Position: Q3 2025 in Review

Soleus Capital Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 10,000 shares — an estimated $838K sold.

Soleus Capital Management first reported a position in SLNO in Q3 2023 and held it in 3 quarters. The position peaked at $10.7M in Q1 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Soleus Capital Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 10,000 Soleno Therapeutics shares in Q3 2025, an estimated $838K.
  • Soleus Capital Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 3 quarters.
  • Soleus Capital Management's Soleno Therapeutics position peaked at $10.7M in Q1 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.